OncoSec Medical to Present at the Sachs Cancer Bio Partnering Forum and Participate in a Panel Discu
OncoSec Medical to Present at the Sachs Cancer Bio Partnering Forum and Participate in a Panel Discussion on Immunotherapies and Cancer Vaccines
SAN DIEGO--(BUSINESS WIRE)-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the Sachs Cancer Bio Partnering Forum at the Westin Copley Place in Boston, Massachusetts, on Tuesday, May 21, at 2:05 PM ET.
In addition, Mr. Dhillon will be participating in a panel discussion titled "Immunotherapies & Cancer Vaccines" to be held on Tuesday, May 21, at 4:00 PM ET. The panel will be chaired by Florian Schodel, CEO, Philimmune LLC, and Mara Goldstein, Senior Analyst, Cantor Fitzgerald.
About the Sachs Cancer Bio Partnering Forum
The Sachs Cancer Bio Partnering Forum is a two-day conference designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. Approximately 300 delegates are expected. There will be presentations by various research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotechs seeking licensing/investment. For more information, visit: http://www.sachsforum.com/boston13/.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
KEYWORDS: United States North America California Massachusetts
The article OncoSec Medical to Present at the Sachs Cancer Bio Partnering Forum and Participate in a Panel Discussion on Immunotherapies and Cancer Vaccines originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.